高危患者经导管主动脉瓣置换术后五年临床结局与瓣膜耐久性
FRANCE-2注册研究纳入法国34个中心4201例因重度主动脉瓣狭窄行TAVR的高危患者,报告5年随访结果。5年全因死亡率为60.8%,严重结构性瓣膜退化(SVD)5年累积发生率2.5%,中重度SVD为13.3%,严重SVD与死亡率无显著差异。
要点
- 5年全因死亡率为60.8%,多数心血管事件集中在术后1个月内。
- 5年严重SVD累积发生率为2.5%,中重度SVD为13.3%。
- 严重SVD患者与非严重SVD患者死亡率无显著差异。
核心结论
- 高危重度主动脉瓣狭窄患者TAVR术后5年随访显示,存活患者临床事件发生率低、SVD水平低,支持TAVR的长期有效性。
研究设计与样本
- FRANCE-2注册研究为观察性注册研究,纳入2010年1月至2012年1月法国34个中心连续4201例因重度主动脉瓣狭窄行TAVR的患者,随访至5年。
主要发现
- 5年全因死亡率为60.8%(n=2478;95%CI 59.3%–62.3%)。
- 多数心血管事件发生于瓣膜植入后第1个月内,此后发生率维持低水平,至5年时每年<2%,但心力衰竭除外。
- 心力衰竭1年发生率为14.3%,随后随时间下降至每年<5%。
- 5年严重SVD和中重度SVD累积发生率分别为2.5%和13.3%。
- 严重SVD与无严重SVD患者死亡率无差异(HR 0.71;95%CI 0.47–1.07;P=0.1)。
临床怎么用
- TAVR术后远期临床事件与SVD发生率低,支持在高危重度主动脉瓣狭窄患者中应用TAVR并长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The FRANCE-2 registry (French Aortic National Corevalve and Edwards) previously reported good early- and medium-term clinical and echocardiographic efficacy for transcatheter aortic valve replacement. We here report 5-year follow-up results from the registry. METHODS: The registry includes all consecutive patients undergoing transcatheter aortic valve replacement for severe aortic stenosis in France. Follow-up is scheduled at 30 days, 6 months, then annually from 1 to 5 years. Clinical events were defined according to the Valve Academic Research Consortium criteria, and hemodynamic structural valve deterioration (SVD) was defined according to the consensus statement by the European Association of Percutaneous Cardiovascular Interventions. RESULTS: Between January 2010 and January 2012, 4201 patients were enrolled in 34 centers. Five-year vital status was available for 95.5% of patients; 88.1% had clinical evaluation or died. Overall, at 5 years, all-cause mortality was 60.8% (n=2478; 95% CI, 59.3% to 62.3%). The majority of cardiovascular events occurred in the first month after valve implantation, and incidence remained low thereafter, at <2% per year up to 5 years, except for heart failure. The rate of heart failure was 14.3% at 1 year, then decreased over time to <5% per year. In cumulative incidence function, the rates of severe SVD and moderate/severe SVD at 5 years were 2.5% and 13.3%, respectively. Mortality did not differ between patients with or without severe SVD (hazard ratio, 0.71; 95% CI, 0.47-1.07; P=0.1). Finally, in the population of patients with severe SVD, 1 patient (1.7%) experienced a stroke, and 8 patients presented ≥1 heart failure event (13.3%). CONCLUSIONS: The 5-year follow-up results of the FRANCE-2 registry represent the largest long-term data set available in a high-risk population. In surviving patients, the low rate of clinical events and the low level of SVD after 1 year support the long-term efficacy of transcatheter aortic valve replacement in both types of transcatheter prosthesis featuring in the registry.
引用
- Didier R, Eltchaninoff H, Donzeau-Gouge P, et al. Five-Year Clinical Outcome and Valve Durability After Transcatheter Aortic Valve Replacement in High-Risk Patients. Circulation. 2018. PMID: 30571260. doi:10.1161/CIRCULATIONAHA.118.036866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。